Urinary Alpha1-Microglobulin: A New Predictor for In-Hospital Mortality in Patients with ST-Segment Elevation...

Area of Science:

• Cardiology
• Biomarkers
• Clinical Prognostics

Background:

• Alpha1-microglobulin (A1MG) is linked to inflammation and oxidation.
• Urinary A1MG (UA1MG) is present in body fluids but its prognostic value in ST-elevated myocardial infarction (STEMI) is unclear.
• Urine test results are often overlooked in predicting hospital prognosis.

Purpose of the Study:

• To investigate the association between UA1MG levels and short-term prognosis in STEMI patients.
• To determine if UA1MG can serve as an independent predictor of in-hospital mortality and major adverse cardiac events (MACEs) in STEMI.

Main Methods:

• Retrospective analysis of 1854 hospitalized STEMI patients.
• Categorization of patients into low, medium, and high UA1MG groups based on admission values.
• Evaluation of in-hospital all-cause deaths, cardiac deaths, and MACEs as primary outcomes.

Main Results:

• Patients with the highest UA1MG levels exhibited significantly higher rates of in-hospital deaths (4.4% vs. 1.0%), cardiac deaths (3.1% vs. 0.6%), and MACEs (8.6% vs. 4.7%) compared to the lowest UA1MG group.
• Multivariate analysis confirmed UA1MG as an independent predictor of all-cause in-hospital mortality (OR 1.109, P=0.008).
• An optimal UA1MG cutoff of 3.23 mg/dL predicted all-cause mortality with an AUC of 0.73 (P<0.001).

Conclusions:

• Admission UA1MG levels are a significant independent prognostic factor for all-cause in-hospital mortality in STEMI patients.
• UA1MG shows potential as a readily accessible biomarker for risk stratification in acute myocardial infarction.
• Further research could explore UA1MG's role in guiding therapeutic strategies for STEMI management.